Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06688992 in advanced melanoma
NCT03159117Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2017
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PF-06688992 in Malignant Melanoma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Recommended Phase 2 Dose at 1 year. Started May 2017; status: completed.
02
Drugs
PF-06688992
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT03159117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03159117.